In the hyper-competitive world of cell therapy, Celyad isn't chasing the mainstream CD19 targets used for leukemia. Instead, they've staked their reputation—and $92.5M in revenue—on the elusive NKG2D receptor, a move that defines their unique position in the oncology landscape.

"Their web traffic is shockingly low for a company of this size, suggesting a massive disconnect between their scientific output and their digital footprint."

The technology stack reveals a company in transition. While they utilize modern frameworks like Tailwind CSS and jQuery, the presence of OpenCart (an e-commerce platform) on a biotech site is unusual, hinting at legacy code or a subdomain repurposing. The lack of structured data and the reliance on generic CMS platforms suggest their digital team is minimal, likely outsourced or deprioritized.

• Revenue stability: $92.5M indicates established partnerships or licensing deals, not just venture capital burn.
• IP focus: Key personnel like Hannes Iserentant (Head IP) suggest a defensive moat around their CAR-T constructs.
• Traffic anomaly: 49% direct traffic is high for a B2B biotech, implying strong brand recall among a small, dedicated professional audience.